Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of “Moderate Buy” by Analysts

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have been given a consensus rating of “Moderate Buy” by the seven analysts that are presently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $7.50.

STTK has been the subject of a number of research reports. Needham & Company LLC restated a “hold” rating on shares of Shattuck Labs in a research note on Thursday, March 27th. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Leerink Partners initiated coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They set an “outperform” rating and a $4.00 price objective on the stock. Finally, HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a research report on Thursday, March 27th.

Hedge Funds Weigh In On Shattuck Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STTK. Barclays PLC grew its stake in Shattuck Labs by 299.5% in the 3rd quarter. Barclays PLC now owns 54,311 shares of the company’s stock valued at $189,000 after buying an additional 40,717 shares during the last quarter. Geode Capital Management LLC boosted its stake in Shattuck Labs by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock valued at $3,184,000 after purchasing an additional 8,133 shares during the period. JPMorgan Chase & Co. grew its holdings in Shattuck Labs by 63.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock valued at $96,000 after buying an additional 10,667 shares during the last quarter. Virtu Financial LLC bought a new position in Shattuck Labs in the 4th quarter worth approximately $30,000. Finally, Takeda Pharmaceutical Co. Ltd. acquired a new position in shares of Shattuck Labs during the fourth quarter worth approximately $624,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Price Performance

Shares of STTK opened at $0.95 on Tuesday. The business’s 50-day moving average is $1.01 and its 200-day moving average is $1.14. The company has a market capitalization of $45.40 million, a price-to-earnings ratio of -0.62 and a beta of 1.74. Shattuck Labs has a fifty-two week low of $0.69 and a fifty-two week high of $11.76.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. Equities research analysts expect that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.